| Patient | Clara Barton |
|---|---|
| Date of birth | 1973-12-25 |
| Identifiers | MRN HR-NI024-SYN; SSN (made up) 000-24-3357 |
| Document date | 2026-04-14 |
| Author | Eleanor Whitcombe, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Twelve-week depression treatment review. [S]
Ms. Barton returns six weeks after sertraline was increased to 100 mg. At the nurse telephone check two weeks after the increase she reported three days of mild nausea and no restlessness or suicidal thoughts. She now has more good days than bad, enjoys her work again, and sleeps about six and a half hours. She has had ten CBT sessions and is using the sleep schedule. She increased to 35 hours a week after the last visit and this week to her new limit of 45 hours, and she has handed the families' correspondence to a colleague. She has missed no doses and has had no side effects since the first few days after the increase. She has had no suicidal thoughts. [S]
| Element | Detail |
|---|---|
| Interval change | More good days than bad; enjoying work again |
| Dose increase | Three days of mild nausea after the increase; nurse check at two weeks with no concerns |
| Sleep | About six and a half hours |
| Work | Up to 45 hours a week; correspondence delegated |
| Safety | No suicidal thoughts |
| PHQ-9 | 7, down from 18 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better; weight up 1.1 kg since intake |
| Gastrointestinal | Negative | No nausea now; no bleeding |
| Genitourinary | Negative | No sexual side effects |
| Psychiatric | Positive | Mild residual low energy on some days; no suicidal thoughts, elevated mood, or racing thoughts |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sertraline 50 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning | Oral route | 2026-01-20 to 2026-03-03 | completed | S |
| Sertraline 100 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning | Oral route | 2026-03-03 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-14 | Body height | 152 | cm | S |
| 2026-04-14 | Body weight | 50.9 | kg | S |
| 2026-04-14 | Body mass index (BMI) [Ratio] | 22 | kg/m2 | S |
| 2026-04-14 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-04-14 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-04-14 | Heart rate | 72 | /min | S |
| 2026-04-14 | Respiratory rate | 14 | /min | S |
| 2026-04-14 | Body temperature | 36.6 | Cel | S |
| 2026-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-04-14 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 4 | {score} | S |
Vital signs recorded on 2026-04-14; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well groomed; brisk |
| Mental status | Alert; mood "much better"; affect reactive with humor; thought process linear; no suicidal ideation; insight and judgment good |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Major depressive disorder, recurrent, moderate (moderately severe symptoms at intake), after a prolonged humanitarian deployment; synthetic modern diagnosis linked to her documented periods of depression and nervous prostration | active | confirmed | F33.1 | S — Synthetic modern diagnosis. Her periods of depression and nervous prostration are documented in her own words (D); calling them major depression is a retrospective interpretation (R), and no diagnosis was made in her lifetime. |
| Occupational burnout after eighteen months leading field medical relief in a war zone | active | confirmed | Z73.0 | S — Synthetic contributing factor echoing her documented exhaustion after wartime relief work; burnout is an occupational phenomenon, not a mental disorder. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 7, down 61 percent from 18: response; remission not yet reached |
| Survey | GAD-7 | With the PHQ-9 when anxiety symptoms were present at baseline | Completed today | 4, down from 9 |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior since the last visit; PHQ-9 item 9 scored 0. Safety plan reviewed |
| Medication safety | Tolerability check two weeks after the dose increase | 2 weeks after each dose change | Completed today | Done by nurse telephone call two weeks after the increase: three days of mild nausea, no activation or suicidal thoughts |
| Medication safety | Adherence and adverse-effect review | Every visit during active treatment | Completed today | No missed doses; no side effects now |
| Self-management | Psychotherapy, sleep, work hours, and social contact | Every visit during active treatment | Completed today | Ten CBT sessions; sleep about six and a half hours; 45-hour week; peer support group advised |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Treated with an SSRI only |
Goal progress:
Guideline basis: VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Care-manager telephone PHQ-9 in about four weeks; depression review in two months. Next scheduled visit 2026-06-16: five-month depression review in continuation treatment. [S]